Cambridge neural interface spinout Bios will use some of the seed capital to develop an interface between prosthetic objects and the human nervous system.
Bios, a UK-based neural interface spinout of University of Cambridge, has attracted $4.5m in a seed round co-led by VC fund AME Cloud Ventures, TechCrunch reported on Tuesday.
VC firm Real Ventures and angel investor Ariel Poler also co-led the round, which featured early-stage funds Endure Capital, Heuristic Capital Partners and K5 Ventures, as well as private investor Charles Songhurst.
Founded in 2015 as Cambridge Bio-Augmentation Systems, Bios is a neural engineering company hoping to create interfaces between machines and the human nervous systems through technologies including neuroscience, machine learning, big data and applied materials.
The spinout’s first product is described as a biological “USB connector” that will support the development of a prosthetic interface device (PID) enabling the nervous system to control prosthetic objects.
Bios recently opened an R&D base in Montreal, Canada, and is preparing the PID for clinical trials.
The seed capital will enable it to double its technical staff, further develop its core technologies and extend support for commercial and academic partners.
Bios was co-founded by Emil Hewage, a former Cambridge doctoral researcher who specialises in computational neuroscience and machine learning, together with Oliver Armitage, a PhD candidate focused on biointerfaces and tissue engineering.